Novartis (NVS) Stock Forecast & Price Target

$103.50 +0.41 (+0.40%)

(As of 11:01 AM ET)

Novartis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 9 Analyst Ratings

Sell
1

Hold
8

Buy
0

Based on 9 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 9 analysts, 1 has given a sell rating, and 8 have given a hold rating for NVS.

Consensus Price Target

$121.50
17.39% Upside

According to the 9 analysts' twelve-month price targets for Novartis, the average price target is $121.50. The highest price target for NVS is $130.00, while the lowest price target for NVS is $114.00. The average price target represents a forecasted upside of 17.39% from the current price of $103.50.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

NVS Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$121.50	$120.70	$118.13	$85.00
Forecasted Upside	17.39% Upside	5.54% Upside	-0.37% Downside	-12.45% Downside
Consensus Rating	Reduce	Reduce	Hold	Hold

Trump said you could learn something from this man (Ad)

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

Here’s everything you need to know.

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.89	2.80	2.50
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	17.86% Upside	26,931.55% Upside	9.81% Upside
News Sentiment Rating	Positive News See Recent NVS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/19/2024	Erste Group Bank 3 of 5 stars		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets 4 of 5 stars		Boost Target	Market Perform ➝ Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America 4 of 5 stars		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/5/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%
1/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral
12/14/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	CHF 82 ➝ CHF 84
12/5/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:25 AM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG has a strong track record of consistent quarterly earnings, beating analysts' estimates, which indicates financial stability and growth potential.
With a current stock price of $116.22, Novartis AG is trading near its 52-week high, showing positive momentum and potential for further price appreciation.
The company has a healthy return on equity of 34.56%, indicating efficient use of shareholder funds to generate profits.
Novartis AG offers a diverse portfolio of prescription medicines for patients and physicians, providing revenue stability and growth opportunities in the healthcare sector.
Analysts forecast that Novartis AG will post 7.52 earnings per share for the current year, suggesting strong earnings growth potential.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Novartis AG's stock price has experienced fluctuations, with a beta of 0.57, indicating higher volatility compared to the market average.
The company's debt-to-equity ratio of 0.47 may raise concerns about its financial leverage and ability to manage debt obligations.
Novartis AG's price-to-earnings ratio of 15.68 may suggest that the stock is currently trading at a premium valuation, potentially limiting immediate upside for investors.
While the company has a strong net margin of 33.76%, any decline in profitability could impact shareholder returns and stock performance.
Investors should consider market conditions and regulatory challenges in the healthcare industry that could affect Novartis AG's future growth prospects.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $121.50, with a high forecast of $130.00 and a low forecast of $114.00.
: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There is currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NVS shares.
: According to analysts, Novartis's stock has a predicted upside of 17.39% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 2 downgrades by analysts.
: Novartis has been rated by research analysts at Bank of America, BMO Capital Markets, Erste Group Bank, Jefferies Financial Group, and The Goldman Sachs Group in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NYSE:NVS) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target